Surajit Kalita

Surajit Kalita

Auto-generated profile, based on publicly available information

Surajit Kalita

Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401, Israel

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Journal of the American Chemical Society
Verified
Journal Article
Open access
KDKshatresh Dutta Dubey
Kshatresh Dutta Dubey
TSThijs Stuyver
Thijs Stuyver
SKSurajit Kalita
Surajit Kalita
SSSason Shaik
Sason Shaik
When and how do external electric fields (EEF) lead to catalysis in the presence of a (polar or nonpolar) solvent? This is the question that is addressed here using a combination of molecular-dynamics (MD) simulations, quantum-mechanical / molecular-mechanical with EEF, and quantum-mechanical / (local) electric-field calculations. The manuscript focuses on a model-reaction, the Menshutkin reaction between CH3I and pyridine in three solvents of varying polarity. Using MD simulations, we find that the EEF causes the solvent to undergo organization; the solvent molecules gradually align with the applied field as the field strength increases. The collective orientation of the solvent-molecules modifies the electrostatic environment around the Menshutkin species and induces a global electric field pointing in the opposite direction of the applied EEF. The combination of these two entangled effects leads to partial-or-complete screening of the EEF, with the extent of screening being proportional to the polarity/polarizability of the solvent. Nevertheless, we find that the catalysis of the Menshutkin reaction inevitably emerges once the EEF exceeds the opposing field of the organizing solvent, i.e. once polarization of the Menshutkin complex is observed to set in. Overall, our analysis provides a lucid and pictorial interpretation of the behavior of solutions in the presence of EEFs and indicates that EEF-mediated catalysis should in principle be feasible in bulk setups, especially for nonpolar and mildly polar solvents. By application of the charge-transfer paradigm, it is shown that the emergence of OEEF catalysis in solution can be generalized to other reactions as well.

3 September 2020 in ACS Catalysis
Verified
Journal Article
Closed access
SKSurajit Kalita
Surajit Kalita
SSSason Shaik
Sason Shaik
HKHemanta K. Kisan
Hemanta K. Kisan
KDKshatresh Dutta Dubey
Kshatresh Dutta Dubey

13 October 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
SKSurajit Kalita
Surajit Kalita
SSSason Shaik
Sason Shaik
KDKshatresh Dutta Dubey
Kshatresh Dutta Dubey
An enzyme which is capable of catalyzing C–H amination reactions is considered to be a dream tool for chemists due to its pharmaceutical potential and greener approach. Recently, the Arnold group achieved this feat using an engineered CYP411 enzyme, which further undergoes a random directed evolution which increases its efficiency and selectivity. The present study provides mechanistic insight and the root cause of the success of these mutations to enhance the reactivity and selectivity of the mutant enzyme. This is achieved by means of comprehensive MD simulations and hybrid QM/MM calculations. The study shows that the efficient C–H amination by the engineered CYP411 is a combined outcome of electronic and steric effects. The mutation of the axial cysteine ligand to serine relays electron density to the Fe ion in the heme, and thereby enhances the bonding capability of the heme-iron to the nitrogen atom of the tosyl azide. In comparison, the native cysteine-ligated P450 cannot bind the tosyl azide. Additionally, the A78V and A82L mutations in P411 provide ‘bulk’ to the active site which increases the enantioselectivity via a steric effect. At the same time, the QM/MM calculations elucidate the C–H amination by the iron nitrenoid, revealing a mechanism analogous to Compound I in the native C–H hydroxylation by P450.

7 February 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
SYShalini Yadav
Shalini Yadav
SSSason Shaik
Sason Shaik
SSShakir Ali Siddiqui
Shakir Ali Siddiqui
SKSurajit Kalita
Surajit Kalita
KDKshatresh Dutta Dubey
Kshatresh Dutta Dubey

27 April 2022 in ACS Catalysis
Verified
Journal Article
Closed access
SKSurajit Kalita
Surajit Kalita
SSSason Shaik
Sason Shaik
KDKshatresh Dutta Dubey
Kshatresh Dutta Dubey

3 February 2023 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SKSurajit Kalita
Surajit Kalita
HBHagai Bergman
Hagai Bergman
KDKshatresh Dutta Dubey
Kshatresh Dutta Dubey
SSSason Shaik
Sason Shaik
Alzheimer's disease is one of the most common neurodegenerative conditions, which are ascribed to extracellular accumulation of β-amyloid peptides into plaques. This phenomenon seems to typify other related neurodegenerative diseases. The present study uses classical molecular-dynamics simulations to decipher the aggregation-disintegration behavior of β-amyloid peptide plaques in the presence of static and oscillating oriented external electric fields (OEEFs). A long-term disintegration of such plaques is highly desirable since this may improve the prospects of therapeutic treatments of Alzheimer's disease and of other neurodegenerative diseases typified by senile plaques. Our study illustrates the spontaneous aggregation of the β-amyloid, its prevention and breakdown when OEEF is applied, and the fate of the broken aggregate when the OEEF is removed. Notably, we demonstrate that the usage of an oscillating OEEF on β-amyloid aggregates appears to lead to an irreversible disintegration. Insight is provided into the root causes of the various modes of aggregation, as well as into the different fates of OEEF-induced disintegration in oscillating vs static fields. Finally, our simulation results are compared to the well-established TTFields and the Deep Brain Stimulation (DBS) therapies, which are currently used options for treatments of Alzheimer's disease and other related neurodegenerative diseases.